Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 569-572
10.1182/blood-2022-162559